ArticleCytotherapy2026
Implantation of human mesenchymal stromal cell pellet for therapeutic angiogenesis.
Article in Cytotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Angiogenesis in Lung Regeneration and Aging.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Mesenchymal Stem Cell-Lysate Sustained-Release Nano-Hydrogel Alleviates Spinal Cord Injury by Inhibiting Ferroptosis and Mitochondrial Intrinsic Apoptosis.International dental journal · 2026Article
- Needle gauge and length effects on human stem cell viability during injection: a comprehensive review.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND
aimsAlthough mesenchymal stromal cell (MSC) therapy holds great potential, therapeutic efficacy, which is predicted by pre-clinical studies, has fallen short of expectations in most clinical studies. This discrepancy may arise from inadequate standardization of cell preparations, unstable cell engraftment and insufficient understanding of cellular fitness in vivo due to the lack of a relevant experimental system in which human MSCs stably engraft and the behavior of the MSCs can be systemically analyzed. MSCs stimulate angiogenesis and accelerate tissue/organ regeneration by releasing various bioactive factors (secretome). In this study, we established a system in which an implanted human MSC pellet stably engrafts and the angiogenic ability of the MSCs can be systematically analyzed in vivo.
methodsSurgically excised human subcutaneous white adipose tissue (4 g) was enzymatically digested and MSCs were successfully isolated from 237 patients (19-91 years old). MSCs isolated from donors (13 clones) less than 65 years old were used for the experiments.
resultsMSCs stimulated sprouting of human adipose endothelial cells in endothelial cell-organoids in vitro. Various angiogenesis-related factors were detected in cell lysate and conditioned medium from cultured non-frozen human MSCs in vitro. Within 21 days after initial cell isolation, an implantable MSC pellet was created by culturing human MSCs (5 × 10
conclusionsFabrication and implantation of an MSC pellet can be leveraged not only to pre-clinically explore fitness of human MSCs in vivo but also to potentiate efficacy of MSC therapy in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.